摘要
目的评价多西他赛联合异环磷酰胺(IFO)方案与多西他赛单药治疗复发性非小细胞肺癌的疗效和不良反应。方法应用多西他赛单药方案(T)与多西他赛联合异环磷酰胺(IFO)方案(TI)治疗复发性非小细胞肺癌共55例。其中T组28例,TI组27例,2组病例的临床资料具有可比性。结果T、TI两组有效率分别为25%(7/28)、22%(6/27),两组间临床近期疗效无显著差异(P﹥0.05)。两组主要毒性反应均表现为骨髓抑制和消化道反应,其中骨髓抑制两组的发生情况相似,无显著差异(P﹥0.05)。消化道反应T组明显低于TI组,有显著差异(P﹤0.05)。结论多西他赛单药与TI方案在复发性非小细胞肺癌治疗的疗效上无显著性差异。多西他赛单药仍是标准治疗方案。
Objective To evaluate the effect and side reaction of docetaxel regimen and docetaxel combined with ifosfamide regimen in the treatment of recurrent advanced non-small-cell Lung cancer. Methods Docetaxel regimen and docetaxel combined with ifos-famide were used to treat 55 patients of recurrent non-small cell lung cancer. 28 patients were treated with T ann, 27 patients with TI arm, patients in two groups were well-matched in basic characteristics. Results The reponse rate was 25% （7/28） in group T arm, 22% （6/27） in group TI ann. The efficacy in two groups had no significant difference （P〉0.05）. The major toxicities were bone marrow depression and nausea and vomiting reaction, showing no significant difference （P〉0.05） between two groups in bone marrow depression. The incidence of nausea and vomiting was significantly higher in the TI arm than in the T arm（P〈0.05）. Conclusions There are no significant differences in terms of response rates in docetaxel combined with ifosfamide doublet and docetaxel single agent in the treatment for the patients with recurrent advanced non-small-cell lung cancer. The standard treatment of the advanced non-smallcell lung cancer which has performed docetaxe.
